Top

Published in:

02-04-2022 | Pancreatic Cancer

Connecting the Human Microbiome and Pancreatic Cancer

Authors: Rachel E. Sexton, Md Hafiz Uddin, Sahar Bannoura, Husain Yar Khan, Yousef Mzannar, Yiwei Li, Amro Aboukameel, Mohammad Najeeb Al-Hallak, Bayan Al-Share, Amr Mohamed, Misako Nagasaka, Bassel El-Rayes, Asfar S. Azmi

Published in: Cancer and Metastasis Reviews | Issue 2/2022

Abstract

Pancreatic cancer is a deadly disease that is increasing in incidence throughout the world. There are no clear causal factors associated with the incidence of pancreatic cancer; however, some correlation to smoking, diabetes and alcohol has been described. Recently, a few studies have linked the human microbiome (oral and gastrointestinal tract) to pancreatic cancer development. A perturbed microbiome has been shown to alter normal cells while promoting cancer-related processes such as increased cell signaling, immune system evasion and invasion. In this article, we will review in detail the alterations within the gut and oral microbiome that have been linked to pancreatic cancer and explore the ability of other microbiomes, such as the lung and skin microbiome, to contribute to disease development. Understanding ways to identify a perturbed microbiome can result in advancements in pancreatic cancer research and allow for prevention, earlier detection and alternative treatment strategies for patients.

Seer.cancer.gov. Cancer Stat Facts: Pancreatic Cancer. Surveillance, Epidemiology and End Results Program. Accessed 11/12/2021.

Stark, A., & Eibl, G. (2015). Pancreatic Ductal Adenocarcinoma. Pancreapedia: Exocrine Pancreas Knowledge Base. https://doi.org/10.3998/panc.2015.14

Alkassis, S., Yazdanpanah, O., & Philip, P. A. (2021). BRCA mutations in pancreatic cancer and progress in their targeting. Expert Opinion on Therapeutic Targets, 25(7), 547–557. https://doi.org/10.1080/14728222.2021.1957462CrossRefPubMed

Ro, C., Chai, W., Yu, V. E., & Yu, R. (2013). Pancreatic neuroendocrine tumors: Biology, diagnosis, and treatment. Chinese Journal of Cancer, 32(6), 312–324. https://doi.org/10.5732/cjc.012.10295CrossRefPubMedPubMedCentral

Shulman, S. T., Friedmann, H. C., & Sims, R. H. (2007). Theodor Escherich: The first pediatric infectious diseases physician? Clinical Infectious Diseases, 45(8), 1025–1029. https://doi.org/10.1086/521946CrossRefPubMed

McFarland, L. V. (2015). From Yaks to Yogurt: The History, Development and Current Use of Probiotics. Clinical Infectious Disease., 60(2), S85–S90. https://doi.org/10.1093/cid.civ054CrossRef

Cani, P. D. (2018). Human gut microbiome: Hopes, threats and promises. Gut, 67, 1716–1725. https://doi.org/10.1136/gutjnl-2018-316723CrossRefPubMed

Nayfach, S., Páez-Espino, D., Call, L., et al. (2021). Metagenomic compendium of 189,680 DNA viruses from the human gut microbiome. Nature Microbiology, 6, 960–970. https://doi.org/10.1038/s41564-021-00928-6CrossRefPubMedPubMedCentral

Deo, P. N., & Deshmukh, R. (2019). Oral microbiome: Unveiling the fundamentals. Journal of oral and maxillofacial pathology: JOMFP, 23(1), 122–128. https://doi.org/10.4103/jomfp.JOMFP_304_18CrossRefPubMedPubMedCentral

10.

Cresci, G. A., & Bawden, E. (2015). Gut Microbiome: What We Do and Don’t Know. Nutrition in Clinical Practice, 30(6), 734–746. https://doi.org/10.1177/0884533615609899CrossRefPubMedPubMedCentral

11.

Komiyama, K., Tynan, J. J., Habbick, B. F., Duncan, D. E., & Liepert, D. J. (1985). Pseudomonas aeruginosa in the oral cavity and sputum of patients with cystic fibrosis. Oral Surgery, Oral Medicine, and Oral Pathology, 59(6), 590–594. https://doi.org/10.1016/0030-4220(85)90187-2CrossRefPubMed

12.

DeGruttola, A. K., Low, D., Mizoguchi, A., & Mizoguchi, E. (2016). Current Understanding of Dysbiosis in Disease in Human and Animal Models. Inflammatory Bowel Diseases, 22(5), 1137–1150. https://doi.org/10.1097/MIB.0000000000000750CrossRefPubMed

13.

Slots, J., & Rams, T. E. (1991). New views on periodontal microbiota in special patient categories. Journal of Clinical Periodontology, 18(6), 411–420. https://doi.org/10.1111/j.1600-051x.1991.tb02309.xCrossRefPubMed

14.

Benjamin R. M. (2010). Oral health: the silent epidemic. Public health reports (Washington, D.C.: 1974), 125(2), 158–159. https://doi.org/10.1177/003335491012500202

15.

Leishman, S. J., Do, H. L., & Ford, P. J. (2010). Cardiovascular disease and the role of oral bacteria. Journal of oral microbiology, 2. https://doi.org/10.3402/jom.v2i0.5781.10.3402/jom.v2i0.5781

16.

Tong, Y., Zheng, L., Qing, P., Zhao, H., Li, Y., Su, L., Zhang, Q., Zhao, Y., Luo, Y., & Liu, Y. (2020). Oral Microbiota Perturbations are Linked to High Risk for Rheumatoid Arthritis. Frontiers in Cellular and Infection Microbiology. https://doi.org/10.3389/fcimb.2019.00475CrossRefPubMedPubMedCentral

17.

Meurman J. H. (2010). Oral microbiota and cancer. Journal of oral microbiology, 2. https://doi.org/10.3402/jom.v2i0.5195.10.3402/jom.v2i0.5195

18.

Northridge, M. E., Kumar, A., & Kaur, R. (2020). Disparities in Access to Oral Health Care. Annual review of public health, 41, 513–535. https://doi.org/10.1146/annurev-publhealth-040119-094318CrossRefPubMedPubMedCentral

19.

Winkler, J. R., & Robertson, P. B. (1992). Periodontal disease associated with HIV infection. Oral Surgery, Oral Medicine, and Oral Pathology, 73(2), 145–150. https://doi.org/10.1016/0030-4220(92)90186-tCrossRefPubMed

20.

Koonin, E. V., Mushegian, A. R., & Rudd, K. E. (1996). Sequencing and analysis of bacterial genomes. Current Biology., 6(4), 404–416. https://doi.org/10.1016/S0960-9822(02)00508-0CrossRefPubMed

21.

Clarridge J. E., 3rd (2004). Impact of 16S rRNA gene sequence analysis for identification of bacteria on clinical microbiology and infectious diseases. Clinical microbiology reviews, 17(4), 840–862. https://doi.org/10.1128/CMR.17.4.840-862.2004

22.

Grice, E. A., Kong, H. H., Conlan, S., Deming, C. B., Davis, J., Young, A. C., NISC Comparative Sequencing Program, Bouffard, G. G., Blakesley, R. W., Murray, P. R., Green, E. D., Turner, M. L., & Segre, J. A. (2009). Topographical and temporal diversity of the human skin microbiome. Science (New York, N.Y.), 324(5931), 1190–1192. https://doi.org/10.1126/science.1171700

23.

Luna, P. C. (2020). Skin Microbiome as Years Go By. American journal of clinical dermatology, 21(Suppl 1), 12–17. https://doi.org/10.1007/s40257-020-00549-5CrossRefPubMedPubMedCentral

24.

Boxberger, M., Cenizo, V., Cassir, N., et al. (2021). Challenges in exploring and manipulating the human skin microbiome. Microbiome, 9, 125. https://doi.org/10.1186/s40168-021-01062-5CrossRefPubMedPubMedCentral

25.

Grice, E. A., Kong, H. H., Conlan, S., Deming, C. B., Davis, J., Young, A. C., et al. (2009). Topographical and temporal diversity of the human skin microbiome. Science, 324, 1190–1192.CrossRef

26.

Nørreslet, L. B., Agner, T., & Clausen, M. L. (2020). The Skin Microbiome in Inflammatory Skin Diseases. Current Dermatology Reports, 9, 141–151. https://doi.org/10.1007/s13671-020-00297-zCrossRef

27.

Busse, K., & Liao, W. (2010). Which Psoriasis Patients Develop Psoriatic Arthritis? Psoriasis forum, 16(4), 17–25.CrossRef

28.

Chiu, H. Y., Hsieh, C. F., Chiang, Y. T., Huang, W. F., & Tsai, T. F. (2016). The Risk of Chronic Pancreatitis in Patients with Psoriasis: A Population-Based Cohort Study. PLoS ONE, 11(7), e0160041. https://doi.org/10.1371/journal.pone.0160041CrossRefPubMedPubMedCentral

29.

Pfister, H., & zur Hausen, H. (1978). Seroepidemiological studies of human papilloma virus (HPV-1) infections. International Journal of Cancer, 21(2), 161–5. https://doi.org/10.1002/ijc.2910210206CrossRefPubMed

30.

Tong, T. R., Chan, A., Lai, T. W., Chan, O. W., Lee, K. C., Lo, S. T., Lung, R., Li, J. Y., & Chow, T. C. (2007). Identification of HPV-16 in Borderline Mucinous Cystic Neoplasm of Pancreas. International journal of biomedical science : IJBS, 3(1), 72–75.PubMedPubMedCentral

31.

Liu, N. N., Ma, Q., Ge, Y., Yi, C. X., Wei, L. Q., Tan, J. C., Chu, Q., Li, J. Q., Zhang, P., & Wang, H. (2020). Microbiome dysbiosis in lung cancer: From composition to therapy. NPJ precision oncology, 4(1), 33. https://doi.org/10.1038/s41698-020-00138-zCrossRefPubMedPubMedCentral

32.

Wang, H., Liu, J. S., Peng, S. H., Deng, X. Y., Zhu, D. M., Javidiparsijani, S., Wang, G. R., Li, D. Q., Li, L. X., Wang, Y. C., & Luo, J. M. (2013). Gut-lung crosstalk in pulmonary involvement with inflammatory bowel diseases. World Journal of Gastroenterology, 19(40), 6794–6804. https://doi.org/10.3748/wjg.v19.i40.6794CrossRefPubMedPubMedCentral

33.

Bowerman, K. L., Rehman, S. F., Vaughan, A., et al. (2020). Disease-associated gut microbiome and metabolome changes in patients with chronic obstructive pulmonary disease. Nature Communications, 11, 5886. https://doi.org/10.1038/s41467-020-19701-0CrossRefPubMedPubMedCentral

34.

Witt, H., Apte, M. V., Keim, V., & Wilson, J. S. (2007). Chronic pancreatitis: Challenges and advances in pathogenesis, genetics, diagnosis, and therapy. Gastroenterology, 132(4), 1557–1573. https://doi.org/10.1053/j.gastro.2007.03.001CrossRefPubMed

35.

Omary, M. B., Lugea, A., Lowe, A. W., & Pandol, S. J. (2007). The pancreatic stellate cell: A star on the rise in pancreatic diseases. The Journal of Clinical Investigation, 117(1), 50–59. https://doi.org/10.1172/JCI30082CrossRefPubMedPubMedCentral

36.

Ohlund, D., Handly-Santana, A., Biffi, G., Elyada, E., Almeida, A. S., Ponz-Sarvise, M., Corbo, V., Oni, T. E., Hearn, S. A., Lee, E. J., et al. (2017). Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer. Journal of Experimental Medicine., 214(3), 579–596.CrossRef

37.

Domen, A., Quatannens, D., Zanivan, S., Deben, C., Van Audenaerde, J., Smits, E., Wouters, A., Lardon, F., Roeyen, G., Verhoeven, Y., Janssens, A., Vandamme, T., van Dam, P., Peeters, M., & Prenen, H. (2021). Cancer-Associated Fibroblasts as a Common Orchestrator of Therapy Resistance in Lung and Pancreatic Cancer. Cancers, 13(5), 987. https://doi.org/10.3390/cancers13050987CrossRefPubMedPubMedCentral

38.

Swidnicka-Siergiejko, A., Gomez-Chou, S., Cruz-Monserrate, Z., et al. (2017). Chronic inflammation initiates multiple forms of K-Ras-independent mouse pancreatic cancer in the absence of TP53. Oncogene, 36, 3149–3158. https://doi.org/10.1038/onc.2016.461CrossRefPubMed

39.

Tjomsland, V., Bojmar, L., Sandstrom, P., Brathail, C., Messmer, D., Spangeus, A., & Larsson, M. (2013). IL-1a Expression in Pancreatic Ductal Adenocarcinoma Affects the Tumor Cell Migration and Is Regulated by the p38MAPK Signaling Pathway. PLoS ONE. https://doi.org/10.1371/journal.pone.0070874CrossRefPubMedPubMedCentral

40.

Steele, N. G., Biffi, G., Kemp, S. B., Zhang, Y., Drouillard, D., Syu, L., Hao, Y., Oni, T. E., Brosnan, E., Elyada, E., Doshi, A., Hansma, C., Espinoza, C., Abbas, A., The, S., Irizarry-Negron, V., Halbrook, C. J., Franks, N. E., Hoffman, M. T., … Pasca di Magliano, M. (2021). Inhibition of Hedgehog Signaling Alters Fibroblast Composition in Pancreatic Cancer. Clinical Cancer Research, 27(7), 2023–2037. https://doi.org/10.1158/1078-0432.CCR-20-3715CrossRefPubMedPubMedCentral

41.

Gaitanidis, A., Patel, D., Nilubol, N., Tirosh, A., Sadowski, S., & Kebebew, E. (2018). Markers of Systemic Inflammatory Response are Prognostic Factors in Patients with Pancreatic Neuroendocrine Tumors (PNETs): A Prospective Analysis. Annals of Surgical Oncology, 25(1), 122–130. https://doi.org/10.1245/s10434-017-6241-4CrossRefPubMed

42.

Cigrovski Bervkovic, M., Cacev, T., Catela Ivkovic, T., Zjacic-Rotkvic, V., & Kapitanovic, S. (2014). New Insights into the Role of Chronic Inflammation and Cytokines in the Etiopathogenesis of Gastroenteropancreatic Neuroendocrine Tumors. Neuroendocrinology, 99, 75–84. https://doi.org/10.1159/0003624339CrossRef

43.

Cives, M., Pelle’, E., Quaresmini, D., Rizzo, F. M., Tucci, M., & Silvestris, F. (2019). The Tumor Microenvironment in Neuroendocrine Tumors: Biology and Therapeutic Implications. Neuroendocrinology, 109(2), 83–99. https://doi.org/10.1159/000497355CrossRefPubMed

44.

Zambirinis, C. P., Pushalkar, S., Saxena, D., & Miller, G. (2014). Pancreatic cancer, inflammation, and microbiome. Cancer Journal (Sudbury, Mass.), 20(3), 195–202. https://doi.org/10.1097/PPO.0000000000000045CrossRef

45.

Bulajic, M., Panic, N., & Löhr, J. M. (2014). Helicobacter pylori and pancreatic diseases. World Journal of Gastrointestinal Pathophysiology, 5(4), 380–383. https://doi.org/10.4291/wjgp.v5.i4.380CrossRefPubMedPubMedCentral

46.

Ikebe, M., Kitaura, Y., Nakamura, M., Tanaka, H., Yamasaki, A., Nagai, S., Wada, J., Yanai, K., Koga, K., Sato, N., Kubo, M., Tanaka, M., Onishi, H., & Katano, M. (2009). Lipopolysaccharide (LPS) increases the invasive ability of pancreatic cancer cells through the TLR4/MyD88 signaling pathway. Journal of Surgical Oncology, 100(8), 725–731. https://doi.org/10.1002/jso.21392CrossRefPubMed

47.

Vaccaro, M. I., Calvo, E. L., Suburo, A. M., Sordelli, D. O., Lanosa, G., & Iovanna, J. L. (2000). Lipopolysaccharide directly affects pancreatic acinar cells: Implications on acute pancreatitis pathophysiology. Digestive Diseases and Sciences, 45(5), 915–926. https://doi.org/10.1023/a:1005521007609CrossRefPubMed

48.

Hoefs, J. C., Renner, I. G., Askhcavai, M., & Redeker, A. G. (1980). Hepatitis B surface antigen in pancreatic and biliary secretions. Gastroenterology, 79(2), 191–194.CrossRef

49.

Hassan, M. M., Li, D., El-Deeb, A. S., Wolff, R. A., Bondy, M. L., Davila, M., & Abbruzzese, J. L. (2008). Association between hepatitis B virus and pancreatic cancer. Journal of clinical oncology : Official journal of the American Society of Clinical Oncology, 26(28), 4557–4562. https://doi.org/10.1200/JCO.2008.17.3526CrossRef

50.

Xia JY, Zhou YY, Zhao YY. (2005) [Relationship between hepatitis B virus in gastric mucosa and syndrome of disharmony between liver and stomach in patients with chronic hepatitis B]. Zhong Xi Yi Jie He Xue Bao. 3(1):19–22. Chinese. https://doi.org/10.3736/jcim20050107.

51.

Seong, M., Kang, T. W., & Ha, S. Y. (2015). Pancreatic Candidiasis That Mimics a Malignant Pancreatic Cystic Tumor on Magnetic Resonance Imaging: A Case Report in an Immunocompetent Patient. Korean Journal of Radiology, 16(6), 1253–1256. https://doi.org/10.3348/kjr.2015.16.6.1253CrossRefPubMedPubMedCentral

52.

Chung, L., Liang, J., Lin, C., Sun, L., & Kao, C. (2017). Cancer risk in patients with candidiasis: A nationwide population-based cohort study. Oncotarget, 8, 63562–63573. https://doi.org/10.18632/oncotarget.18855CrossRefPubMedPubMedCentral

53.

Wei, A. L., Li, M., Li, G. Q., Wang, X., Hu, W. M., Li, Z. L., Yuan, J., Liu, H. Y., Zhou, L. L., Li, K., Li, A., & Fu, M. R. (2020). Oral microbiome and pancreatic cancer. World Journal of Gastroenterology, 26(48), 7679–7692. https://doi.org/10.3748/wjg.v26.i48.7679CrossRefPubMedPubMedCentral

54.

Petrick, J. L., Wilkinson, J. E., Michaud, D. S., et al. (2021). The oral microbiome in relation to pancreatic cancer risk in African Americans. British Journal of Cancer. https://doi.org/10.1038/s41416-021-01578-5CrossRefPubMed

55.

Fan, X., Alekseyenko, A. V., Wu, J., Peters, B. A., Jacobs, E. J., Gapstur, S. M., Purdue, M. P., Abnet, C. C., Stolzenberg-Solomon, R., Miller, G., Ravel, J., Hayes, R. B., & Ahn, J. (2018). Human oral microbiome and prospective risk for pancreatic cancer: A population-based nested case-control study. Gut, 67(1), 120–127. https://doi.org/10.1136/gutjnl-2016-312580CrossRefPubMed

56.

Gerlovin, H., Michaud, D. S., Cozier, Y. C., & Palmer, J. R. (2019). Oral Health in Relation to Pancreatic Cancer Risk in African American Women. Cancer Epidemiology, Biomarkers & Prevention, 28(4), 675–679. https://doi.org/10.1158/1055-9965.EPI-18-1053CrossRef

57.

Michaud, D. S., & Izard, J. (2014). Microbiota, oral microbiome, and pancreatic cancer. Cancer journal (Sudbury, Mass.), 20(3), 203–206. https://doi.org/10.1097/PPO.0000000000000046CrossRef

58.

Lovegrove, J. M. (2004). Dental plaque revisited: Bacteria associated with periodontal disease. Journal of the New Zealand Society of Periodontology, 87, 7–21.

59.

Zhang, W., Zhang, K., Zhang, P., Zheng, J., Min, C., & Li, X. (2021). Research Progress of Pancreas-Related Microorganisms and Pancreatic Cancer. Frontiers in oncology, 10, 604531. https://doi.org/10.3389/fonc.2020.604531CrossRefPubMedPubMedCentral

60.

Grice, E. A., & Segre, J. A. (2011). The skin microbiome. Nature reviews. Microbiology, 9(4), 244–253. https://doi.org/10.1038/nrmicro2537CrossRefPubMedPubMedCentral

61.

Bellotti, R., Speth, C., Adolph, T. E., Lass-Flörl, C., Effenberger, M., Öfner, D., & Maglione, M. (2021). Micro- and Mycobiota Dysbiosis in Pancreatic Ductal Adenocarcinoma Development. Cancers, 13(14), 3431. https://doi.org/10.3390/cancers13143431CrossRefPubMedPubMedCentral

62.

Aykut, B., Pushalkar, S., Chen, R., Li, Q., Abengozar, R., Kim, J. I., Shadaloey, S. A., Wu, D., Preiss, P., Verma, N., Guo, Y., Saxena, A., Vardhan, M., Diskin, B., Wang, W., Leinwand, J., Kurz, E., Kochen Rossi, J. A., Hundeyin, M., … Miller, G. (2019). The fungal mycobiome promotes pancreatic oncogenesis via activation of MBL. Nature, 574(7777), 264–267. https://doi.org/10.1038/s41586-019-1608-2CrossRefPubMedPubMedCentral

63.

Rudramurthy, S. M., Honnavar, P., Dogra, S., Yegneswaran, P. P., Handa, S., & Chakrabarti, A. (2014). Association of Malassezia species with dandruff. The Indian journal of medical research, 139(3), 431–437.PubMedPubMedCentral

64.

Schaffer, J. N., & Pearson, M. M. (2015). Proteus mirabilis and Urinary Tract Infections. Microbiology spectrum, 3(5), https://doi.org/10.1128/microbiolspec.UTI-0017-2013. https://doi.org/10.1128/microbiolspec.UTI-0017-2013

65.

Löwik CAM, Zijlstra WP, Knobben BAS, Ploegmakers JJW, Dijkstra B, de Vries AJ, Kampinga GA, Mithoe G, Al Moujahid A, Jutte PC, Wouthuyzen-Bakker M; Northern Infection Network Joint Arthroplasty (NINJA). (2019) Obese patients have higher rates of polymicrobial and Gram-negative early periprosthetic joint infections of the hip than non-obese patients. PLoS One. 14(4):e0215035. https://doi.org/10.1371/journal.pone.0215035.

66.

Hu, F., Guo, F., Zhu, Y., Zhou, Q., Li, T., Xiang, H., & Shang, D. (2020). IL-17 in pancreatic disease: Pathogenesis and pharmacotherapy. American Journal of Cancer Research, 10(11), 3551–3564.PubMedPubMedCentral

67.

Jin, X., Dai, L., Ma, Y., et al. (2020). Implications of HIF-1α in the tumorigenesis and progression of pancreatic cancer. Cancer Cell International, 20, 273. https://doi.org/10.1186/s12935-020-01370-0CrossRefPubMedPubMedCentral

68.

Magne, F., Gotteland, M., Gauthier, L., Zazueta, A., Pesoa, S., Navarrete, P., & Balamurugan, R. (2020). The Firmicutes/Bacteroidetes Ratio: A Relevant Marker of Gut Dysbiosis in Obese Patients? Nutrients, 12(5), 1474. https://doi.org/10.3390/nu12051474CrossRefPubMedCentral

69.

Wexler, H. M. (2007). Bacteroides: The good, the bad, and the nitty-gritty. Clinical Microbiology Reviews, 20(4), 593–621. https://doi.org/10.1128/CMR.00008-07CrossRefPubMedPubMedCentral

70.

Ottman, N., Smidt, H., de Vos, W. M., & Belzer, C. (2012). The function of our microbiota: Who is out there and what do they do? Frontiers in Cellular and Infection Microbiology, 2, 104. https://doi.org/10.3389/fcimb.2012.00104CrossRefPubMedPubMedCentral

71.

Larsen, N., Vogensen, F. K., van den Berg, F. W., Nielsen, D. S., Andreasen, A. S., Pedersen, B. K., Al-Soud, W. A., Sørensen, S. J., Hansen, L. H., & Jakobsen, M. (2010). Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults. PLoS ONE, 5(2), e9085. https://doi.org/10.1371/journal.pone.0009085CrossRefPubMedPubMedCentral

72.

Agus, A; Clement, K; Sokol, H. (2020) Gut microbiota-derives metabolites as central regulators in metabolic disorders. Recent Advances in Basic Science. 70(6). https://doi.org/10.1136/gutjnl-2020-323071

73.

Pannala, R., Basu, A., Petersen, G. M., & Chari, S. T. (2009). New-onset diabetes: A potential clue to the early diagnosis of pancreatic cancer. The Lancet. Oncology, 10(1), 88–95. https://doi.org/10.1016/S1470-2045(08)70337-1CrossRefPubMedPubMedCentral

74.

Rosato, V., Tavani, A., Bosetti, C., Pelucchi, C., Talamini, R., Polesel, J., Serraino, D., Negri, E., & La Vecchia, C. (2011). Metabolic syndrome and pancreatic cancer risk: A case-control study in Italy and meta-analysis. Metabolism, 60(10), 1372–1378. https://doi.org/10.1016/j.metabol.2011.03.005CrossRefPubMed

75.

Huang, J. Y., Luu, H. N., Butler, L. M., Midttun, Ø., Ulvik, A., Wang, R., Jin, A., Gao, Y. T., Tan, Y., Ueland, P. M., Koh, W. P., & Yuan, J. M. (2020). A prospective evaluation of serum methionine-related metabolites in relation to pancreatic cancer risk in two prospective cohort studies. International Journal of Cancer, 147(7), 1917–1927. https://doi.org/10.1002/ijc.32994CrossRefPubMed

76.

Feng, H. Y., & Chen, Y. C. (2016). Role of bile acids in carcinogenesis of pancreatic cancer: An old topic with new perspective. World journal of gastroenterology, 22(33), 7463–7477. https://doi.org/10.3748/wjg.v22.i33.7463CrossRefPubMedPubMedCentral

77.

Tucker, O. N., Dannenberg, A. J., Yang, E. K., & Fahey, T. J. (2004). 3rd Bile acids induce cyclooxygenase-2 expression in human pancreatic cancer cell lines. Carcinogenesis, 25, 419–423.CrossRef

78.

Phelan, J. P., Reen, F. J., Caparros-Martin, J. A., O’Connor, R., & O’Gara, F. (2017). Rethinking the bile acid/gut microbiome axis in cancer. Oncotarget, 8(70), 115736–115747. https://doi.org/10.18632/oncotarget.22803CrossRefPubMedPubMedCentral

79.

Yuan, L., Zhang, S., Li, H., Yang, F., Mushtaq, N., Ullah, S., Shi, Y., An, C., & Xu, J. (2018). The influence of gut microbiota dysbiosis to the efficacy of 5-Fluorouracil treatment on colorectal cancer. Biomedicine & Pharmacotherapy, 108, 184–193. https://doi.org/10.1016/j.biopha.2018.08.165CrossRef

80.

Thomas, H. (2017). Intra-tumour bacteria promote gemcitabine resistance in pancreatic adenocarcinoma. Nature Reviews. Gastroenterology & Hepatology, 14, 632. https://doi.org/10.1038/nrgastro.2017.142CrossRef

81.

Panebianco, C., Adamberg, K., Jaagura, M., Copetti, M., Fontana, A., Adamberg, S., Kolk, K., Vilu, R., Andriulli, A., & Pazienza, V. (2018). Influence of gemcitabine chemotherapy on the microbiota of pancreatic cancer xenografted mice. Cancer Chemotherapy and Pharmacology, 81(4), 773–782. https://doi.org/10.1007/s00280-018-3549-0CrossRefPubMed

82.

Badgeley, A., Anwar, H., Modi, K., Murphy, P., & Lakshmikuttyamma, A. (2021). Effect of probiotics and gut microbiota on anti-cancer drugs: Mechanistic perspectives. Biochimica et Biophysica Acta - Reviews on Cancer, 1875(1), 188494. https://doi.org/10.1016/j.bbcan.2020.188494CrossRefPubMed

83.

Huang, Y., Yang, W., Liu, H., Duan, J., Zhang, Y., Liu, M., Li, H., Hou, Z., & Wu, K. K. (2012). Effect of high-dose methotrexate chemotherapy on intestinal Bifidobacteria, Lactobacillus and Escherichia coli in children with acute lymphoblastic leukemia. Experimental Biology and Medicine (Maywood, N.J.), 237(3), 305–311. https://doi.org/10.1258/ebm.2011.011297CrossRef

84.

Mucciolo, G., Roux, C., Scagliotti, A., Brugiapaglia, S., Novelli, F., & Cappello, P. (2020). The dark side of immunotherapy: Pancreatic cancer. Cancer Drug Resistance., 3, 491–520. https://doi.org/10.20517/cdr.2020.13CrossRefPubMedPubMedCentral

85.

O’Reilly, E. M., Oh, D. Y., Dhani, N., Renouf, D. J., Lee, M. A., Sun, W., Fisher, G., Hezel, A., Chang, S. C., Vlahovic, G., Takahashi, O., Yang, Y., Fitts, D., & Philip, P. A. (2019). Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma: A Phase 2 Randomized Clinical Trial. JAMA oncology, 5(10), 1431–1438. https://doi.org/10.1001/jamaoncol.2019.1588CrossRefPubMedPubMedCentral

86.

Torphy, R. J., Zhu, Y., & Schulick, R. D. (2018). Immunotherapy for pancreatic cancer: Barriers and breakthroughs. Annals of Gastroenterological Surgery, 2(4), 274–281. https://doi.org/10.1002/ags3.12176CrossRefPubMedPubMedCentral

87.

Matson, V., Chervin, C. S., & Gajewski, T. F. (2021). Cancer and the Microbiome-Influence of the Commensal Microbiota on Cancer, Immune Responses, and Immunotherapy. Gastroenterology, 160(2), 600–613. https://doi.org/10.1053/j.gastro.2020.11.041CrossRefPubMed

88.

Oster, P., Vaillant, L., Riva, E., McMillan, B., Begka, C., Truntzer, C., Richard, C., Leblond, M. M., Messaoudene, M., Machremi, E., et al. (2020). Helicobacter pylori infection has a detrimental impact on the efficacy of cancer immunotherapies. Gut. https://doi.org/10.1136/gutjnl-2020-323392CrossRef

89.

Otieno, S; Jain, A.L.; Mohammed, O; Patel, J.R.; Collyer, J; Deleeuw, P; Husain, A; Weir, A.B. (2021) Positive association between Helicobacter pylori infection and pancreatic cancer: A Case control study. Journal of Clinical Oncology. e16243.

90.

Li, S., Fuhler, G. M., Bn, N., Jose, T., Bruno, M. J., Peppelenbosch, M. P., & Konstantinov, S. R. (2017). Pancreatic cyst fluid harbors a unique microbiome. Microbiome., 5(1), 147. https://doi.org/10.1186/s40168-017-0363-6CrossRefPubMedPubMedCentral

91.

Vétizou, M., Pitt, J. M., Daillère, R., Lepage, P., Waldschmitt, N., Flament, C., Rusakiewicz, S., Routy, B., Roberti, M. P., Duong, C. P., Poirier-Colame, V., Roux, A., Becharef, S., Formenti, S., Golden, E., Cording, S., Eberl, G., Schlitzer, A., Ginhoux, F., Mani, S., et al. (2015). Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science (New York, N.Y.), 350(6264), 1079–1084. https://doi.org/10.1126/science.aad1329CrossRef

92.

Chaput, N., Lepage, P., Coutzac, C., Soularue, E., Le Roux, K., Monot, C., Boselli, L., Routier, E., Cassard, L., Collins, M., Vaysse, T., Marthey, L., Eggermont, A., Asvatourian, V., Lanoy, E., Mateus, C., Robert, C., & Carbonnel, F. (2017). Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. Annals of Oncology, 28(6), 1368–1379. https://doi.org/10.1093/annonc/mdx108.Erratum.In:AnnOncol.2019Dec1;30(12):2012CrossRefPubMed

93.

Lopès, A., Billard, E., Casse, A. H., Villéger, R., Veziant, J., Roche, G., Carrier, G., Sauvanet, P., Briat, A., Pagès, F., Naimi, S., Pezet, D., Barnich, N., Dumas, B., & Bonnet, M. (2020). Colibactin-positive Escherichia coli induce a procarcinogenic immune environment leading to immunotherapy resistance in colorectal cancer. International Journal of Cancer, 146(11), 3147–3159. https://doi.org/10.1002/ijc.32920CrossRefPubMed

94.

Sivan, A., Corrales, L., Hubert, N., Williams, J. B., Aquino-Michaels, K., Earley, Z. M., Benyamin, F. W., Lei, Y. M., Jabri, B., Alegre, M. L., Chang, E. B., & Gajewski, T. F. (2015). Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science, 350(6264), 1084–1089. https://doi.org/10.1126/science.aac4255CrossRefPubMedPubMedCentral

95.

Dutta, D., & Lim, S. H. (2020). Bidirectional interaction between intestinal microbiome and cancer: Opportunities for therapeutic interventions. Biomark Res, 8, 31. https://doi.org/10.1186/s40364-020-00211-6CrossRefPubMedPubMedCentral

96.

Zhang, X., Zhou, Y., Chen, C., et al. (2019). Hepatitis B virus reactivation in cancer patients with positive Hepatitis B surface antigen undergoing PD-1 inhibition. Journal Immunotherapy Cancer, 7, 322. https://doi.org/10.1186/s40425-019-0808-5CrossRef

97.

Goradel NH, Alizadeh A, Hosseinzadeh S, Taghipour M, Ghesmati Z, Arashkia A, Negahdari B. (2021) Oncolytic virotherapy as promising immunotherapy against cancer: mechanisms of resistance to oncolytic viruses. Future Oncol. 25. https://doi.org/10.2217/fon-2021-0802

98.

Conry, R. M., Westbrook, B., McKee, S., & Norwood, T. G. (2018). Talimogene laherparepvec: First in class oncolytic virotherapy. Human Vaccines & Immunotherapeutics, 14(4), 839–846. https://doi.org/10.1080/21645515.2017.1412896CrossRef

99.

Ries, S., & Korn, W. M. (2002). ONYX-015: Mechanisms of action and clinical potential of a replication-selective adenovirus. British Journal of Cancer, 86(1), 5–11. https://doi.org/10.1038/sj.bjc.6600006CrossRefPubMedPubMedCentral

100.

Roussey, J. A., Viglianti, S. P., Teitz-Tennenbaum, S., Olszewski, M. A., & Osterholzer, J. J. (2017). Anti-PD-1 Antibody Treatment Promotes Clearance of Persistent Cryptococcal Lung Infection in Mice. The Journal of Immunology, 199(10), 3535–3546. https://doi.org/10.4049/jimmunol.1700840CrossRefPubMed

101.

Chang, K. C., Burnham, C. A., Compton, S. M., Rasche, D. P., Mazuski, R. J., McDonough, J. S., Unsinger, J., Korman, A. J., Green, J. M., & Hotchkiss, R. S. (2013). Blockade of the negative co-stimulatory molecules PD-1 and CTLA-4 improves survival in primary and secondary fungal sepsis. Critical Care, 17(3), R85. https://doi.org/10.1186/cc12711CrossRefPubMedPubMedCentral

102.

Vernuccio, F., Messina, C., Merz, V., Cannella, R., & Midiri, M. (2021). Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma: Role of the Radiologist and Oncologist in the Era of Precision Medicine. Diagnostics (Basel)., 11(11), 2166. https://doi.org/10.3390/diagnostics11112166CrossRefPubMedPubMedCentral

103.

Krishnan, S., Chadha, A. S., Suh, Y., Chen, H. C., Rao, A., Das, P., Minsky, B. D., Mahmood, U., Delclos, M. E., Sawakuchi, G. O., Beddar, S., Katz, M. H., Fleming, J. B., Javle, M. M., Varadhachary, G. R., Wolff, R. A., & Crane, C. H. (2016). Focal Radiation Therapy Dose Escalation Improves Overall Survival in Locally Advanced Pancreatic Cancer Patients Receiving Induction Chemotherapy and Consolidative Chemoradiation. International Journal of Radiation Oncology, Biology, Physics, 94(4), 755–765. https://doi.org/10.1016/j.ijrobp.2015.12.003CrossRefPubMed

104.

Shen, Y., Zhu, X., Cao, F., Xie, H., Ju, X., Cao, Y., Qing, S., Jia, Z., Gu, L., Fang, F., & Zhang, H. (2021). Re-Irradiation With Stereotactic Body Radiotherapy for In-Field Recurrence of Pancreatic Cancer After Prior Stereotactic Body Radiotherapy: Analysis of 24 Consecutive Cases. Frontiers in Oncology, 11, 729490. https://doi.org/10.3389/fonc.2021.729490CrossRefPubMedPubMedCentral

105.

Kim, Y. S., Kim, J., & Park, S. J. (2015). High-throughput 16S rRNA gene sequencing reveals alterations of mouse intestinal microbiota after radiotherapy. Anaerobe, 33, 1–7. https://doi.org/10.1016/j.anaerobe.2015.01.004CrossRefPubMed

106.

Parker, M.J.; Wearsch, P.A.; Veloo, A.C.M.; PRodriguez-Palacios, A. (2020) The Genus Alistipes: Gut Bacteria with Emerging Implications to Inflammation, Cancer and Mental Health. Front Immunol. https://doi.org/10.3389/fimmu.2020.00906.

107.

Pushalkar, S., Hundeyin, M., Daley, D., Zambrinis, C. P., Kurz, E., Mishra, A., Mohan, N., Aykut, B., Usyk, M., Torres, L. E., et al. (2018). The Pancreatic Cancer Microbiome Promotes Oncogenesis by Induction of Innate and Adaptive Immune Suppression. https://doi.org/10.1158/2159-8290.CD-17-1134CrossRef

108.

109.

Bicker, K. L., & Thompson, P. R. (2013). The protein arginine deiminases: Structure, function, inhibition, and disease. Biopolymers, 99(2), 155–163. https://doi.org/10.1002/bip.22127CrossRefPubMedPubMedCentral

110.

Xin, J., & Song, X. (2016). Role of peptidylarginine deaminase type 4 in gastric cancer. Experimetnatl and Therapeutic Medicine, 3155–60. https://doi.org/10.3892/etm.2016.3798

111.

Bowles, T., Kim, R., Galante, J., Parsons, C., Virudachalam, S., Kung, H., & Bold, R. (2008). International Journal of Cancer, 123(8), 1950–1955. https://doi.org/10.1002/ijc.23723CrossRefPubMedPubMedCentral

112.

Fine, D. H., Patil, A. G., & Velusamy, S. K. (2019). Aggregatibacter actinomycetemcomitans (Aa) Under the Radar: Myths and Misunderstandings of Aa and its role in Aggressive Periodontitis. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2019.00728CrossRefPubMedPubMedCentral

113.

Blum, R., & Kloog, Y. (2014). Metabolism addiction in pancreatic cancer. Cell Death & Disease, 5(2), e1065. https://doi.org/10.1038/cddis.2014.38CrossRef

114.

Cameron, M. E., Yakovenko, A., & Trevino, J. G. (2018). Glucose and Lactate Transport in Pancreatic Cancer: Glycolytic Metabolism Revisited. Journal of Oncology, 2018, 6214838. https://doi.org/10.1155/2018/6214838CrossRefPubMedPubMedCentral

115.

Li, W; Han, L; Ma, Q. (2013) Hydrogen Peroxide Mediates Hyperglycemia-Enhanced Invasive Ability of Pancreatic Cancer Cells Via ERK and P38 MAPK Pathways. Annals of Oncology. 24(4): iv38-iv121. https://doi.org/10.1093/annonc/mdt203.39.

116.

Waghray, M., Cui, Z., Horowitz, J. C., Subramanian, I. M., Martinez, F. J., Toews, G. B., et al. (2005). Hydrogen peroxide is a diffusible paracrine signal for the induction of epithelial cell death by activated myofibroblasts. The FASEB Journal, 19, 854–856.CrossRef

117.

Toullec, A., Gerald, D., Despouy, G., Bourachot, B., Cardon, M., Lefort, S., et al. (2010). Oxidative stress promotes myofibroblast differentiation and tumour spreading. EMBO Molecular Medicine, 2, 211–230. https://doi.org/10.1002/emmm.201000073CrossRefPubMedPubMedCentral

118.

Kobayashi, Y., Nishikawa, M., Hyoudou, K., Yamashita, F., & Hashida, M. (2008). Hydrogen peroxide-mediated nuclear factor kappaB activation in both liver and tumor cells during initial stages of hepatic metastasis. Cancer Science, 99, 1546–1552. https://doi.org/10.1111/j.1349-7006.2008.00856.xCrossRefPubMed

119.

Lisanti, M. P., Martinez-Outschoorn, U. E., Lin, Z., Pavlides, S., Whitaker-Menezes, D., Pestell, R. G., Howell, A., & Sotgia, F. (2011). Hydrogen peroxide fuels aging, inflammation, cancer metabolism and metastasis: the seed and soil also needs “fertilizer.” Cell cycle (Georgetown, Tex.), 10(15), 2440–2449. https://doi.org/10.4161/cc.10.15.16870CrossRef

120.

Fu, Y., Yang, G., Zhu, F., et al. (2014). Antioxidants decrease the apoptotic effect of 5-Fu in colon cancer by regulating Src-dependent caspase-7 phosphorylation. Cell Death & Disease, 5, e983. https://doi.org/10.1038/cddis.2013.509CrossRef

121.

Erudaitius, D., Huang, A., Kazmi, S., Buettner, G. R., & Rodgers, V. G. J. (2017). Peroxporin Expression is an Important Factor for Cancer Cell susceptibility to Therapeutic H202: Implications for Pharmacological Ascorbate Therapy. PLOS ONE., 12(1), e0170442. https://doi.org/10.1371/journal.pone.0170442CrossRefPubMedPubMedCentral

122.

Li, J. J., Zhu, M., Kashyap, P. C., et al. (2021). The role of microbiome in pancreatic cancer. Cancer and Metastasis Reviews, 40, 777–789. https://doi.org/10.1007/s10555-021-09982-2CrossRefPubMed

123.

Graham, F. (2019) Daily briefing: Fecal Transplant linked to patient’s death. Nature Briefing.

124.

Chen, S. M., Chieng, W. W., Huang, S. W., et al. (2020). The synergistic tumor growth-inhibitory effect of probiotic Lactobacillus on transgenic mouse model of pancreatic cancer treated with gemcitabine. Science and Reports, 10, 20319. https://doi.org/10.1038/s41598-020-77322-5CrossRef

125.

Konishi, H., Isozaki, S., Kashima, S., et al. (2021). Probiotic Aspergillus oryzae produces anti-tumor mediator and exerts anti-tumor effects in pancreatic cancer through the p38 MAPK signaling pathway. Science and Reports, 11, 11070. https://doi.org/10.1038/s41598-021-90707-4CrossRef

126.

Kita, A., Fujiya, M., Konishi, H., Tanaka, H., Kashima, S., Iwama, T., Ijiri, M., Murakami, Y., Takauji, S., Goto, T., Sakatani, A., Ando, K., Ueno, N., Ogawa, N., & Okumura, T. (2020). Probiotic-derived ferrichrome inhibits the growth of refractory pancreatic cancer cells. International Journal of Oncology, 57(3), 721–732. https://doi.org/10.3892/ijo.2020.5096CrossRefPubMedPubMedCentral

127.

Oláh, A., Belágyi, T., Pótó, L., Romics, L., Jr., & Bengmark, S. (2007). Synbiotic control of inflammation and infection in severe acute pancreatitis: A prospective, randomized, double blind study. Hepato-Gastroenterology, 54(74), 590–594.PubMed

128.

Yadav, D., & Lowenfels, A. B. (2013). The epidemiology of pancreatitis and pancreatic cancer. Gastroenterology, 144(6), 1252–1261. https://doi.org/10.1053/j.gastro.2013.01.068CrossRefPubMed

129.

Genco, R. J., & Borgnakke, W. S. (2013). Risk factors for periodontal disease. Periodontol 2000, 62(1), 59–94. https://doi.org/10.1111/j.1600-0757.2012.00457.xCrossRefPubMed

130.

Leeming, E. R., Johnson, A. J., Spector, T. D., & Le Roy, C. I. (2019). Effect of Diet on the Gut Microbiota: Rethinking Intervention Duration. Nutrients, 11(12), 2862. https://doi.org/10.3390/nu11122862CrossRefPubMedCentral

131.

Oliver, A., Chase, A. B., Weihe, C., Orchanian, S. B., Riedel, S F., Hendrickson, C. L., Lay, M., Sewall, J. M., Martiny, J. B. H., & Whiteson, K. (2021). High-Fiber, whole-food dietary intervention alters the human gut microbiome but not fecal short chain fatty acids. Journal of Clinical Microbiology. https://doi.org/10.1128/mSystems.00115-21

132.

USDA Economic Research Service. (2020). Key Statistics and Graphics. Accessed 11/30/2021.

133.

Shrider, E. A., Kollar, M., Semega, J. (2021). Income and poverty in the United States: 2020. United States Census Bureau. Accessed 11/30/2021.

134.

Gui, X; Yang, Z; Li, M.D. (2021) Effect of cigarette smoke on gut microbiota: State of knowledge. Frontiers in Physiology. https://doi.org/10.3389/fphys.2021.673341.

135.

Pandol, S. J., Apte, M. V., Wilson, J. S., Gukovskaya, A. S., & Edderkaoui, M. (2012). The burning question: why is smoking a risk factor for pancreatic cancer?. Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.], 12(4), 344–349. https://doi.org/10.1016/j.pan.2012.06.002

136.

Uebanso, T., Shimohata, T., Mawatari, K., & Takahashi, A. (2020). Functional roles of B-vitamins in the gut and gut microbiome. Molecular Nutrition & Food Research, 64(18), 20000426. https://doi.org/10.1002/mnfr.202000426CrossRef

137.

Thomas, R. L., Jiang, L., Adams, J. S., et al. (2020). Vitamin D metabolites and the gut microbiome in older men. Nature Communications, 11, 5997. https://doi.org/10.1038/s41467-020-19793-8CrossRefPubMedPubMedCentral

138.

Farrow, B., Rychahou, P., O’Connor, K. L., & Evers, B. M. (2003). Butyrate inhibits pancreatic cancer invasion. Journal of Gastrointestinal Surgery, 7(7), 864–870. https://doi.org/10.1007/s11605-003-0031-yCrossRefPubMed

139.

Natoni, F., Diolordi, L., Santoni, C., & Gilardini Montani, M. S. (2005). Sodium butyrate sensitises human pancreatic cancer cells to both the intrinsic and the extrinsic apoptotic pathways. Biochimica et Biophysica Acta, 1745(3), 318–329. https://doi.org/10.1016/j.bbamcr.2005.07.003CrossRefPubMed

140.

Chen, J., Zhao, K. N., & Vitetta, L. (2019). Effects of Intestinal Microbial-Elaborated Butyrate on Oncogenic Signaling Pathways. Nutrients, 11(5), 1026. https://doi.org/10.3390/nu11051026CrossRefPubMedCentral

Title: Connecting the Human Microbiome and Pancreatic Cancer
Authors: Rachel E. Sexton
Md Hafiz Uddin
Sahar Bannoura
Husain Yar Khan
Yousef Mzannar
Yiwei Li
Amro Aboukameel
Mohammad Najeeb Al-Hallak
Bayan Al-Share
Amr Mohamed
Misako Nagasaka
Bassel El-Rayes
Asfar S. Azmi
Publication date: 02-04-2022
Publisher: Springer US
Keywords: Pancreatic Cancer
Pancreatic Cancer
Published in: Cancer and Metastasis Reviews / Issue 2/2022
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-022-10022-w

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2022

Nanotechnology-aided advancement in the combating of cancer metastasis

Biographies

Cross-talk between the microbiome and chronic inflammation in esophageal cancer: potential driver of oncogenesis

Heterogeneity and tumor evolution reflected in liquid biopsy in metastatic breast cancer patients: a review

Mechanistic insights into the interplays between neutrophils and other immune cells in cancer development and progression

The cure from within? a review of the microbiome and diet in melanoma

Keynote webinar | Spotlight on antibody–drug conjugates in cancer